July 11 (Bloomberg) -- GlaxoSmithKline Plc said it will seek regulatory approval of its experimental diabetes medicine albiglutide early next year after the drug showed a benefit in a trial.
Patients taking albiglutide, a once-weekly injection, showed a statistically significant reduction in blood sugar levels compared with Merck & Co.’s sitagliptin, London-based Glaxo said in a statement today. The study is one of eight for the drug and the last required to complete the approval registration package, Glaxo said.
Albiglutide, along with the lupus treatment Benlysta and darapladib for heart disease, form a trio of drugs Glaxo has developed with Human Genome Sciences Inc. If approved, the product would compete with existing medicines from Amylin Pharmaceuticals Inc. and Novo Nordisk A/S, as well as other experimental drugs being developed by Sanofi and Eli Lilly & Co.
To contact the reporter on this story: Makiko Kitamura in London at firstname.lastname@example.org.
To contact the editor responsible for this story: Phil Serafino at email@example.com